RIGEL PHARMACEUTICALS, INC.;RIGEL PHARMACEUTICALS; INC.
发明人:
SINGH RAJINDER,RAJINDER SINGH,ARGADE ANKUSH,ANKUSH ARGADE,PAYAN DONALD G.,DONALD G. PAYAN,MOLINEAUX SUSAN,SUSAN MOLINEAUX,HOLLAND SACHA J.,SACHA J. HOLLAND,CLOUGH JEFFREY,JEFFREY CLOUGH,KEIM HOLGER,HO,HOLGER KEIM,KE
申请号：
PL373530
公开号：
PL214988B1
申请日:
2003.01.31
申请国别(地区):
PL
年份:
2013
代理人:
摘要：
The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signalling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signalling cascades.
